For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Thymalin: origin, composition and research history

Research Library › Bioregulators & Thymic

Thymalin is a mixture of peptides extracted from calf thymus, developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Kirov Military Medical Academy in Leningrad and reported as a new preparation in the early 1980s. It is not a single defined molecule. As of 22 Oct 2026 it is registered as a prescription medicine in Russia and is not FDA-approved.

Key facts

TypePeptide extract (a mixture, not one defined molecule)
Derived fromThymus glands of cattle
First describedThymus-extract work from 1974; thymalin papers from 1981-1982
Developed byVladimir Khavinson and V. G. Morozov, Kirov Military Medical Academy, Leningrad
Proposed targetThe thymus and T-cell system; mechanism not established
Regulatory status (Oct 2026)Registered in Russia (certificate dated 21 Jun 2024); not FDA-approved

Who developed it

Thymalin came out of the Kirov Military Medical Academy in Leningrad (now St. Petersburg). Two classmates there, Vladimir Khavinson and V. G. Morozov, began the work as students. According to Khavinson’s own account, they first isolated active peptide substances from cattle thymus during student practice at the Leningrad Meat Factory [1, 2].

Khavinson said the Soviet Ministry of Defense commissioned the program in 1975 [2]. He went on to found the St. Petersburg Institute of Bioregulation and Gerontology in 1992 and died in January 2024 at age 77 [1, 2].

Composition and proposed target

Unlike a synthetic peptide, thymalin is a complex of peptides extracted from the thymus glands of cattle. The thymus is the organ where immune T cells mature. The preparation does not have one defined sequence, and how the extract acts has not been established [1, 2].

Khavinson’s group later built short synthetic peptides modeled on extracts like this one and promoted them under the term “bioregulators” [1]. Thymalin itself remains the original extract-based product.

Why it was created

The original military research program studied how to raise the body’s resistance to harsh conditions. Within it, thymalin was investigated as an immune-modulating preparation, and the 1982 paper described it as a new “immunoregulator” [2, 3].

In the 1980s the developers studied it in Chernobyl cleanup workers and veterans of the war in Afghanistan [2]. In 2003 the same group published a study in older adults followed over several years; the abstract does not describe randomization, and the work has not been independently replicated [4]. A Russian evidence-based-medicine specialist has said these peptides were never tested in a proper comparative experiment [2].

Research timeline

  • 1974: Morozov and Khavinson publish their first thymus-extract paper [5]
  • 1975: Soviet Ministry of Defense commissions the program, per Khavinson [2]
  • 1981-1982: First papers on thymalin, reported as a new immunoregulatory preparation [3]
  • 2003: Developers publish a long-term observational study in older adults [4]
  • Jan 2024: Khavinson dies [2]
  • Jun 2024: Current Russian registration certificate issued [6]

Regulatory status as of October 2026

As of 22 Oct 2026, thymalin is registered as a prescription medicine in Russia. Its current registration certificate, LP-No.(005867)-(RG-RU), is dated 21 Jun 2024, with Samson-Med listed as holder, and replaces an earlier certificate [6, 7].

Thymalin is not FDA-approved. It was not among the peptides FDA addressed in its April 2026 Category 2 update or reviewed at the July 2026 Pharmacy Compounding Advisory Committee meeting [8, 9]. It is not named on the World Anti-Doping Agency’s 2026 Prohibited List [10].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who created thymalin?

Thymalin was developed by Vladimir Khavinson and V. G. Morozov at the Kirov Military Medical Academy in Leningrad, beginning in the 1970s.

Is thymalin FDA approved?

No. As of October 2026 thymalin is registered as a prescription medicine in Russia but is not FDA-approved.

What is thymalin made from?

It is a mixture of peptides extracted from the thymus glands of cattle, not a single synthetic molecule.

What is the difference between thymalin and thymosin alpha-1?

Thymalin is a Russian multi-peptide thymus extract; thymosin alpha-1 is one defined 28-amino-acid peptide isolated in the United States in 1977.

When was thymalin first developed?

Work on the thymus extract began in Leningrad in the early 1970s, the first related paper appeared in 1974, and thymalin was reported as a new preparation in 1981-1982.

Who holds the Russian registration for thymalin?

Russian drug registers list Samson-Med as holder of the current thymalin registration certificate, dated 21 June 2024.

Sources

  1. Khavinson VKh. Curriculum vitae. khavinson.info (official personal site). Link
  2. Barkalova E. Who is "Putin's gerontologist" Vladimir Khavinson and what did he leave behind? Paper (Bumaga), 24 Jan 2024. Link
  3. Khavinson VKh, et al. [Experimental and clinical study of a new immunoregulator preparation, thymalin.] Voen Med Zh. 1982. PMID 7048731. Link
  4. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID 14523363. Link
  5. Morozov VG, Khavinson VKh. [Thymus extract and the healing of experimental burn wounds.] Eksp Khir Anesteziol. 1974. PMID 4459086. Link
  6. RLS (Russian drug register). Thymalin, registration certificate LP-No.(005867)-(RG-RU), 21 Jun 2024, holder Samson-Med, status active. Link
  7. Vidal Russia. Thymalin: RU LP-No.(005867)-(RG-RU) of 21.06.24; previous RU LS-000267. Link
  8. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
  9. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  10. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top